4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results, Misses Expectations By $0.10 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) issued its quarterly earnings data on Friday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Stock Up 1.1 %

FDMT stock opened at $4.53 on Friday. The company has a market cap of $209.41 million, a P/E ratio of -1.59 and a beta of 2.81. 4D Molecular Therapeutics has a twelve month low of $4.20 and a twelve month high of $36.25. The business has a fifty day moving average of $5.22 and a 200-day moving average of $8.59.

Analyst Upgrades and Downgrades

FDMT has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 19th. Bank of America cut their price objective on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Morgan Stanley cut their price objective on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, February 10th. Finally, BMO Capital Markets downgraded 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $40.00 to $15.00 in a research report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.13.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.